Cargando…

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

BACKGROUND AND OBJECTIVES: Patients with diabetes mellitus inject insulin in different regions of the body. This study investigated the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg), a new-generation once-daily basal insulin with an ultra-long duration of action, after su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nosek, Leszek, Coester, Hans-Veit, Roepstorff, Carsten, Thomsen, Henrik F., Kristensen, Niels R., Haahr, Hanne, Heise, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143594/ https://www.ncbi.nlm.nih.gov/pubmed/25124362 http://dx.doi.org/10.1007/s40261-014-0218-x

Ejemplares similares

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2014)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial
por: Heise, Tim, et al.
Publicado: (2016)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
por: Koehler, Gerd, et al.
Publicado: (2013)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
por: Heise, T., et al.
Publicado: (2015)

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
por: Heise, Tim, et al.
Publicado: (2009)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
por: Haahr, Hanne, et al.
Publicado: (2019)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus
por: Plum-Mörschel, Leona, et al.
Publicado: (2023)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism
por: Zijlstra, Eric, et al.
Publicado: (2018)

Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart
por: Pieber, Thomas R., et al.
Publicado: (2019)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion: Time until a change in metabolic effect is induced in patients with type 1 diabetes
por: Heinemann, Lutz, et al.
Publicado: (2009)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
por: Korsatko, S., et al.
Publicado: (2013)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Biodistribution of Insulin Following Massive Insulin Subcutaneous Injection
por: Ikeda, Tomoya, et al.
Publicado: (2022)

Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear
por: Rini, Christopher James, et al.
Publicado: (2015)

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes
por: Zijlstra, Eric, et al.
Publicado: (2017)

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dburd7vsgi5s7pvvjshkj3geqq